Methods and compositions for the treatment of acne

Patent metadata

Field	Value
Publication number	US-10420743-B2
Application number	US-201816033257-A
Country	US
Kind code	B2
Filing date	Jul 12, 2018
Priority date	Jul 12, 2017
Publication date	Sep 24, 2019
Grant date	Sep 24, 2019

Abstract

The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.

First claim

The invention claimed is:

1. A method of treating acne comprising: topically applying onto an affected skin area of a subject in need thereof, once a day for a period of time of up to 12 weeks, a topical medicament which consists of the active agents:
Tretinoin, or a pharmaceutically acceptable salt thereof, in an amount of about 0.1% weight; and
Benzoyl Peroxide in an amount of about 3% weight.

2. The method according to claim 1 , wherein the score of at least one parameter evaluated by an Investigator Cutaneous Safety Assessment is synergistically lower than the score of the parameters evaluated with the same treatment regimen with each of the active agents separately.

3. The method according to claim 2 , wherein said at least one parameter evaluated by the Investigator Cutaneous Safety Assessment is selected from erythema, scaling, pigmentation and any combinations thereof.

4. The method according to claim 1 , wherein the score of at least one parameter evaluated by a Local Tolerability Score is synergistically lower than the score of the parameters evaluated with the same treatment regimen with each of the active agents separately.

5. The method according to claim 4 , wherein said at least one parameter evaluated by the Local Tolerability score is selected from Itching, Burning, Stinging, and any combinations thereof.

6. The method according to claim 1 , wherein said topical medicament is a single dose medicament comprising both said active agents.

7. The method according to claim 1 , wherein said method reduces at least one of:
(i) the number of inflammatory acne lesions by at least 50%; or
(ii) the number of non-inflammatory acne lesions by at least 40%.

8. The method according to claim 7 , wherein said method reduces the number of non-inflammatory acne lesions by at least 40%.

9. The method according to claim 7 , wherein said method reduces the number of inflammatory acne lesions by at least 50%.

10. The method according to claim 7 , wherein said method reduces the number of inflammatory acne lesions by at least 50%; and the number of non-inflammatory acne lesions by at least 40%.

11. The method according to claim 1 , wherein said method improves the IGA success rate by at least 20% compared to the baseline score.

12. The method according to claim 1 , wherein after two weeks storage at 40° C. of the topical medicament, the concentration of all-trans 5,6-epoxy retinoic acid is lower than 1%.

13. A method according to claim 1 , wherein after two weeks storage at 40° C. of the topical medicament, the degradation of said tretinoin is less than 2.5%.

14. The method according to claim 1 , wherein said method potentiates the action of tretinoin in the treatment of acne.

15. The method according to claim 1 , wherein the release rate of said tretinoin from said topical medicament is less than 60% per h.

16. The method according to claim 1 , wherein the release rate of said tretinoin from said topical medicament is less than 60% per h in a medium of 70% IPA (isopropyl alcohol) and 30% water at room temperature.

17. The method according to claim 1 , wherein said at least one active agent of said medicament is encapsulated in a shell.

18. The method according to claim 1 , wherein both active agents, Benzoyl Peroxide and Tretinoin, of said medicament are encapsulated in a shell.

19. The method according to claim 18 , wherein said shell is an inorganic shell.

20. The method according to claim 19 , wherein said shell is a metal oxide or semi-metal oxide inorganic shell.

21. The method according to claim 1 , wherein the score of at least one efficacy parameter is synergistically higher than the parameter evaluated with the same treatment regimen with each of the active agents separately.

22. The method according to claim 21 , wherein said efficacy parameter is selected from at least one of IGA success rate, mean reduction in inflammatory lesions count, mean reduction in non-inflammatory lesion count, mean reduction in acne symptom domain, mean reduction in acne impact domain and mean reduction in verbal rating scale.

Assignees

• Sol Gel Tech Ltd

Inventors

• Toledano Ofer
• Nov Ori

Classifications

• A61K9/006

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• A61K31/203 Primary

  Retinoic acids {; Salts thereof} · CPC title

• A61K9/501

  Inorganic compounds · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K31/327

  Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids · CPC title